# Glucosamine Knee Osteoarthritis Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/glucosamine-knee-osteoarthritis-meta-analysis-evidence-review
Category: evidence-review
Summary: Glucosamine Knee Osteoarthritis Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pa
Last reviewed: 2026-05-28
Reviewed by: Migaku Evidence Review
# Glucosamine Knee Osteoarthritis Meta-analysis: What the Evidence Says

## Quick Answer

Glucosamine Knee Osteoarthritis Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 randomized trial, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Complementary effect of a combined exercise and dietary supplement intervention in individuals with knee osteoarthritis: study protocol for a randomized, double-blind, placebo-controlled trial | randomized trial | 2 | 2026-03-03 | 10.1186/s13063-026-09594-7 |
| Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges | narrative review | 3 | 2025-11-18 | 10.1021/acsptsci.5c00521 |

## What The Sources Report

- Exercise improves balance, reduces fall risk, enhance walking function and postural control, alleviates pain and improves mobility. [Čeh Tina (2026); evidence level 2]
- Consumption of dietary supplements, such as glucosamine, is common in KOA treatment, though the clinical benefits remain inconclusive with conflicting evidence regarding their effectiveness and recommendations. [Čeh Tina (2026); evidence level 2]
- ,, d d N Figure Chondroitin sulfate (CS) is an anionic, sulfated
glycosaminoglycan
found in various connective tissues, including cartilage, bone, ligaments,
tendons, and skin. [Silva Vitor Alfredo de Santana (2025); evidence level 3]
- In terrestrial animals, it is predominantly
found as monosulfated disaccharides at the 4-O or 6-O positions of
GalNAc (CS-A and CS-C, respectively), along with a small percentage
of nonsulfated disaccharides (CS-0). [Silva Vitor Alfredo de Santana (2025); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For glucosamine knee osteoarthritis meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Čeh Tina (2026). Complementary effect of a combined exercise and dietary supplement intervention in individuals with knee osteoarthritis: study protocol for a randomized, double-blind, placebo-controlled trial. DOI: 10.1186/s13063-026-09594-7. PMCID: PMC13063509. PMID: 41772729. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13063509/
- Silva Vitor Alfredo de Santana (2025). Impact of Symptomatic
Slow-Acting Drugs on Inflammatory
Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges. DOI: 10.1021/acsptsci.5c00521. PMCID: PMC12707266. PMID: 41409165. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12707266/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.